{
  "usdmVersion": "4.0",
  "systemName": "Protocol2USDM",
  "systemVersion": "6.2.0",
  "study": {
    "id": "ae306c93-28c5-43da-af52-7221c8545409",
    "name": "",
    "instanceType": "Study",
    "versions": [
      {
        "id": "eb91b381-a2f2-494e-be1c-ef3ace9e3a72",
        "versionIdentifier": "1.0",
        "rationale": "Initial protocol version",
        "instanceType": "StudyVersion",
        "studyDesigns": [
          {
            "id": "sd_1",
            "name": "Study Design",
            "rationale": "Protocol-defined study design",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "c0331f9c-0d51-491d-9441-75596507e672",
              "instanceType": "AliasCode",
              "standardCode": {
                "id": "ed40c9ee-132a-4f27-b677-3945164a10ce",
                "code": "C49656",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              }
            },
            "model": {
              "id": "d43022fe-4fe7-4680-a6b0-fcd7eaa1fee2",
              "code": "C82638",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Single Group Study",
              "instanceType": "Code"
            },
            "epochs": [
              {
                "id": "epoch_1",
                "name": "Screening",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "b6428be4-bcc8-41a2-bc24-f17bddeb4ec1",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "epoch_2",
                "name": "During Treatment",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "0519d410-f214-42a9-a399-f29a81d8d981",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              },
              {
                "id": "epoch_3",
                "name": "Disease Progression",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "85973b9d-d204-42ef-85ec-2ce21f77ddb8",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                }
              }
            ],
            "activities": [
              {
                "id": "grp_1",
                "name": "Local Testing",
                "instanceType": "Activity",
                "childIds": [
                  "act_1",
                  "act_2",
                  "act_3",
                  "act_4"
                ]
              },
              {
                "id": "grp_2",
                "name": "Central Testing",
                "instanceType": "Activity",
                "childIds": [
                  "act_5",
                  "act_6",
                  "act_7"
                ]
              },
              {
                "id": "act_1",
                "name": "Disease characterization (morphology, and either immunohistochemistry, immunofluorescence, or flow cytometry)",
                "instanceType": "Activity",
                "description": "Disease characterization (morphology, and either immunohistochemistry, immunofluorescence, or flow cytometry)"
              },
              {
                "id": "act_2",
                "name": "Cytogenetic analysis by conventional karyotype or FISH",
                "instanceType": "Activity",
                "description": "Cytogenetic analysis by conventional karyotype or FISH"
              },
              {
                "id": "act_3",
                "name": "Evaluate Plasma cell percentage in the bone marrow to confirm CR",
                "instanceType": "Activity",
                "description": "Evaluate Plasma cell percentage in the bone marrow to confirm CR"
              },
              {
                "id": "act_4",
                "name": "Evaluate clonality of plasma cells (by flow cytometry, IHC or IF) in the bone marrow to confirm sCR",
                "instanceType": "Activity",
                "description": "Evaluate clonality of plasma cells (by flow cytometry, IHC or IF**) in the bone marrow to confirm sCR",
                "originalName": "Evaluate clonality of plasma cells (by flow cytometry, IHC or IF**) in the bone marrow to confirm sCR",
                "footnoteRefs": [
                  "asterisk",
                  "asterisk"
                ]
              },
              {
                "id": "act_5",
                "name": "MRD and molecular subtyping",
                "instanceType": "Activity",
                "description": "MRD and molecular subtyping: a portion of bone marrow aspirates collected at screening will be sent to a central laboratory."
              },
              {
                "id": "act_6",
                "name": "Bone marrow aspirate for MRD assessment",
                "instanceType": "Activity",
                "description": "A portion of bone marrow aspirates collected at time of suspected CR/sCR, and 12, 18, 24, 30, 36, 48, and 60 (+/- 1) months post C1D1, will be analyzed for MRD*."
              },
              {
                "id": "act_7",
                "name": "Bone marrow aspirate to evaluate mechanisms of daratumumab resistance",
                "instanceType": "Activity",
                "description": "If feasible, a bone marrow aspirate is requested to be collected from subjects at disease progression and sent to central laboratory to evaluate mechanisms of daratumumab resistance."
              }
            ],
            "encounters": [
              {
                "id": "enc_1",
                "name": "Screening (Baseline)",
                "instanceType": "Encounter",
                "type": {
                  "id": "2f329cdc-2217-4ba7-8f77-f86d564b0fc7",
                  "code": "C48262",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening",
                  "instanceType": "Code"
                },
                "epochId": "epoch_1"
              },
              {
                "id": "enc_2",
                "name": "Treatment (Suspected CR/sCR)",
                "instanceType": "Encounter",
                "type": {
                  "id": "600c53eb-5012-4c4b-85da-f132ebb75bb4",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "epoch_2"
              },
              {
                "id": "enc_3",
                "name": "Treatment (Post C1D1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "06599767-0538-4de4-81e1-932dab17208f",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "epoch_2"
              },
              {
                "id": "enc_4",
                "name": "Disease Progression Visit",
                "instanceType": "Encounter",
                "type": {
                  "id": "98c092e8-3094-4f40-a5da-ff36ebe4afe4",
                  "code": "C99156",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Scheduled Visit",
                  "instanceType": "Code"
                },
                "epochId": "epoch_3"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "timeline_1",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "1307dcb3-d283-479d-a0a4-12bcaa0e6d8a",
                "instances": [
                  {
                    "id": "1307dcb3-d283-479d-a0a4-12bcaa0e6d8a",
                    "activityIds": [
                      "act_1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_1",
                    "encounterId": "enc_1"
                  },
                  {
                    "id": "6f3af851-e535-45df-a55d-b4b382f7480c",
                    "activityIds": [
                      "act_2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_1",
                    "encounterId": "enc_1"
                  },
                  {
                    "id": "d378e511-c9a0-4e8e-bdac-b4ceade53afe",
                    "activityIds": [
                      "act_5"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_1",
                    "encounterId": "enc_1"
                  },
                  {
                    "id": "7508de46-d0d0-4ddc-bc93-ad830f14533f",
                    "activityIds": [
                      "act_3"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_2",
                    "encounterId": "enc_2"
                  },
                  {
                    "id": "d2afcd42-6626-49e7-a7ac-afb7a26e0299",
                    "activityIds": [
                      "act_4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_2",
                    "encounterId": "enc_2"
                  },
                  {
                    "id": "a83cf786-7d96-4cbe-8efa-7be92ce72bb1",
                    "activityIds": [
                      "act_6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_2",
                    "encounterId": "enc_2"
                  },
                  {
                    "id": "6cb5d714-1c3a-4543-90e3-f9fd8ddd285c",
                    "activityIds": [
                      "act_6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_3",
                    "encounterId": "enc_3"
                  },
                  {
                    "id": "e33562e9-2b4c-4a20-ac2d-b7cfe2f390de",
                    "activityIds": [
                      "act_7"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_4",
                    "encounterId": "enc_4"
                  }
                ]
              }
            ],
            "notes": [
              {
                "id": "soa_fn_1",
                "text": "CR: complete response; FISH: fluorescence in situ hybridization; MRD: minimal residual disease; sCR: stringent complete response",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "soa_fn_2",
                "text": "* If one of these time points occurs within 1 month of suspected CR/sCR, a repeat bone marrow will not be requested. These bone marrow tests will only be required if patient's response is near CR or better by blood and urine evaluations.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "soa_fn_3",
                "text": "** Immunohistochemistry or immunofluorescence (both require kappa/lambda ratio from analysis of â‰¥100 plasma cells) or 2 to 4 color flow cytometry are acceptable methods to evaluate plasma cell clonality.",
                "instanceType": "CommentAnnotation"
              }
            ],
            "activityGroups": [
              {
                "id": "grp_1",
                "name": "Local Testing",
                "description": null,
                "childIds": [
                  "act_1",
                  "act_2",
                  "act_3",
                  "act_4"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Disease characterization (morphology, and either immunohistochemistry, immunofluorescence, or flow cytometry)",
                  "Cytogenetic analysis by conventional karyotype or FISH",
                  "Evaluate Plasma cell percentage in the bone marrow to confirm CR",
                  "Evaluate clonality of plasma cells (by flow cytometry, IHC or IF**) in the bone marrow to confirm sCR"
                ]
              },
              {
                "id": "grp_2",
                "name": "Central Testing",
                "description": null,
                "childIds": [
                  "act_5",
                  "act_6",
                  "act_7"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "MRD and molecular subtyping",
                  "Bone marrow aspirate for MRD assessment",
                  "Bone marrow aspirate to evaluate mechanisms of daratumumab resistance"
                ]
              }
            ]
          }
        ]
      }
    ]
  }
}